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George L Balalis and Sarah K Thompson*Abstract
Lymph node status is the most important prognostic factor in esophageal cancer. Through improved detection of
lymph node metastases, using the sentinel lymph node concept, accurate staging and more tailored therapy may be
achieved. This review article outlines two principle ways in which the sentinel lymph node concept could dramatically
influence current standard of care for patients with esophageal cancer. We discuss three limitations to universal
acceptance of the technique, and propose next steps for increasing enthusiasm amongst physicians and surgeons
including the development of a universal tracer, and improved contrast agents with novel dual-modality ‘visibility’.
Keywords: Sentinel lymph node, Esophageal cancer, Micrometastasis, Isolated tumor cell, Endoscopic mucosal
resectionIntroduction
In the United Kingdom, the rate of death from esophageal
cancer in men has increased by more than 65% since
the 1970’s [1,2]. Over the years, there has been some
improvement in treatment outcomes, with neoadjuvant
therapies and better patient selection [3,4]. There is
still however much room for improvement, as current
survival rates for resectable disease remain less than
50% at five years.
Regional lymph node status is the single most important
prognostic factor for patients with esophageal cancer [5].
It is this prognostic factor that has spawned considerable
interest in the sentinel lymph node (SLN) concept, as
a method for decreasing the extent of surgery, as well
as improving staging of patients, by concentrating the
pathologist’s attention on 1 or 2 important lymph nodes.
The sentinel lymph node (SLN) concept, first described
by Morton in the early 1990s, depicts the preferential
lymphatic metastasis of a tumor to one or more regional
nodes. It is the gold standard for patients with breast
cancer and malignant melanoma [6-10]. The ALMANAC
trial, demonstrated a marked reduction in morbidity and
mortality associated with SLN biopsy compared to routine* Correspondence: sarah.thompson@adelaide.edu.au
Department of Surgery, Level 5, Eleanor Harrald Building, Royal Adelaide
Hospital, Adelaide, South Australia 5000, Australia
© 2014 Balalis and Thompson; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.axillary lymphadenectomy, in patients with breast cancer
[11,12]. This has been further demonstrated in several
meta-analyses and randomised control trials [13]. In
melanoma patients, it allows 80% of patients to be
spared a formal lymph node dissection, avoiding the
complications of lymphadenectomy; post-operative
infection, seroma, long-term stiffness, sensory changes
in a peripheral limb dissection, and most importantly,
lymphedema [14,15]. Due to its low false-negative
rate, quoted at around 1%, SLN biopsy negative patients
can be assumed to have no microscopic disease in the
remainder of the lymphatic basin [14,16].
So why has the SLN biopsy not become standard of




There are two principal ways in which routine SLN
biopsy in patients with esophageal cancer could dra-
matically influence current treatment options.
Endoscopic Mucosal Resection/Endoscopic Submucosal
Resection (EMR/ESR)
Similar to breast cancer and melanoma patients, more
accurate preoperative SLN detection could improved Central Ltd. This is an Open Access article distributed under the terms of the
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esophageal cancer, and potentially avoid the need for
an esophagectomy. The risk of nodal disease in pT1a
(intra-mucosal) lesions has been shown in most studies to
be less than 5%, compared to 12 to 37% in pT1b
(submucosal) lesions [17-20]. A recent study by
Manner et al. describes successful ESR of esophageal
cancers restricted to the upper third of the submucosa
(pT1b sm1 lesions) in 66 patients over a 15-year time
period [21]. They achieved an 87% complete endoluminal
remission rate and, in patients with small focal lesions less
than 2cm in size, a 97% complete remission rate. In this
paper, they started with double the number of patients,
but excluded those with high-risk features for lymph node
metastasis. If we could preoperatively assess lymph node
involvement with precision, up to 88% of pT1b sm1
patients could avoid a highly morbid esophagectomy, and
instead undergo a much less invasive ESR. At present
however, Sepesi et al., have concluded that superficial
submucosal esophageal adenocarcinoma should not be
treated by endoscopic resection alone, until more accurate
predictors of nodal spread are found [22].
Currently, there is no randomized controlled trial,
which compares EMR or ESR to esophagectomy for early
esophageal cancer (pT1). Various retrospective analyses
show that EMR/ESR is comparable to esophagectomy,
with similar complete remission rates and 5-year overall
survival. EMR/ESR has also been shown to result in less
morbidity and mortality [23-25]. These studies however
suffer from their retrospective nature, heterogeneity in
patient groups, and heterogeneity in treatment modalities.
It appears that, at present, pT1a esophageal cancer can be
treated quite safely with EMR alone, however pT1b
cancers warrant a more invasive esophagectomy and
lymphadenectomy until we can improve on current
preoperative investigations [26].
Histopathological assessment
Selective identification of the most important lymph
nodes allows the pathologist to “ultra stage” these nodes
with serial sectioning, immunohistochemistry (IHC),
and/or reverse-transcriptase polymerase chain reaction
(RT-PCR). In an ideal world, all resected lymph nodes
would undergo this rigorous assessment. However routine
serial sectioning and IHC is prohibitively expensive and
time consuming, and therefore a more selective approach
are required to ensure that only the most important nodes
are selected for the pathologist.
Why is such a detailed pathological assessment necessary?
The 7th Edition of AJCC Cancer Staging Manual upstages
patients with a breast cancer ≤20 mm with nodal microme-
tastases only from Stage 1A to Stage 1B, to reflect a poorer
outcome [27]. Accordingly, nodal micrometastases are clas-
sified pN1mi, and not pN0mi. At the current time however,isolated tumor cells (ITCs), are still considered pN0 disease
even though a New England Journal of Medicine paper,
published in 2009, found that patients with favorable
early-stage breast cancer and either micrometastases or
ITCs in regional lymph nodes had a reduced 5-year rate of
disease-free survival [28].
In esophageal cancer, even in patients with pT1N0M0
disease, micrometastases are associated with a significant
negative impact on survival [29-33]. These occult deposits,
either micrometastases or isolated tumor cells, are not
visible using conventional pathology and require both
serial sectioning and IHC. Further to this, Thompson et al.
identified that isolated tumor cells are as important as
micro-metastases in determining the overall survival of
patients with esophageal cancer [34]. Yonemura et al. also
found that a larger proportion of patients died from
recurrent disease, if found to have isolated tumor cells
[35]. This clearly has important implications for accurate
staging and tailoring therapy, in patients with esophageal
cancer.
Current Limitations
First, and probably most important, the type of radiocolloid
available for clinical use to detect sentinel nodes is strongly
dependent on that particular country’s legislation, which
hinders the development of uniform protocols. A radiocol-
loid should “show rapid transit towards sentinel nodes with
persistent retention in the nodes” [36]. The balance of these
two properties lies in the size of the particle [37]. Smaller
particles allow faster visualization of SLN and better uptake
in metastatic nodes, whilst larger particles have the advan-
tage of a longer retention time and slower transit, which
minimizes detection of nodes downstream to the SLN.
Throughout Europe, 99mTc-albumin is used, compared
to 99mTc-tin fluoride colloid in Japan, 99mTc-sulfur
colloid in North America, and 99mTc-antimony colloid
here in Australia. The size of the colloid ranges from a
100-220nm sulphur, which can be injected one day prior
to surgery, to 10 ± 3 nm antimony that is injected just
prior to the operation [38,39]. Smaller sized colloids
were found to have greater success in preoperative
visualization and intraoperative identification of axillary
sentinel nodes in breast cancer patients, compared to
larger sized colloids [40]. No similar studies exist for
upper gastrointestinal cancer patients.
A second limitation, alluded to earlier, is the logis-
tical issue of injecting the colloid. This is a simple
superficial injection in melanoma and breast cancer
patients. In contrast, the tracer must be injected via
endoscopy/colonoscopy or laparoscopy/thoracoscopy
in patients with a cancer of the gastrointestinal tract.
This is much more invasive than a skin injection and the
timing differs depending on the radiotracer legislated for
use in the country of origin.
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95% of lymph nodes are within 3 cm of the primary
tumor, as demonstrated by van de Ven et al. [41]. This
complicates the detection of lymph nodes preoperatively
by lymphoscintigraphy, with PET/CT scanners often
unable to distinguish positive nodes close to the primary
tumor due to the shine-through effect [38]: “where a
strong radioactive signal from the primary tumor
hinders the SLN detection with radiocolloid.” The inability
to have a clear anatomical pathway preoperatively, to
guide the intraoperative dissection, is a deterrent
towards routine clinical application of the SLN concept.
The incorporation of more spatially accurate imaging
modalities, and better minimally invasive gamma probes
(i.e. with orthogonal 90-degree probes) may avoid interfer-
ence from injected tracer in the primary tumor.
Next steps
As stated above, esophageal cancer should adopt the
SLN concept. It is the only practical method in today’s
economic climate to identify the most important nodes
for detailed histopathological analysis. As well, widespread
adoption of this technique will promote the development
of novel sentinel node tracers, which may even be capable
of non-invasive lymph node staging, and delivery of thera-
peutic agents to disseminated tumor cells within the
nodes. However, as an initial step, we need to improve
upon detection of the SLN in non-superficial cancers.
Second, a universally appropriate tracer is required.
This will provide consensus on methodology, timing
of migration, and results of SLN detection. The timing of
endoscopic injection will therefore be able to be standard-
ized. Probably, a tracer with a longer half-life between
injection and migration to sentinel nodes will be more
appropriate, to enable preoperative imaging.
Third, improved contrast agents are needed, especially
for esophageal cancer. An ideal tracer is one that can
enter the initial lymphatic capillary with ease, and move
freely to the SLN where it is retained. The tracer should
be chemically stable, inexpensive, easily produced and
reproducible, and concentrate in the node without
spillage. It should also have a short transit time, but
remain in the sentinel nodes to allow detection prior
to moving on second-tier nodes. Nanotechnology, the
use of man-made objects, which contain nano-scale
dimensions, may provide the answer [42]. These particles
have many of the properties listed above, and some, such
as supramagnetic iron oxide nanoparticles (SPIONs), have
already been approved for in vivo imaging. For example,
in 16 patients with esophageal cancer, Nishimura et al.
found that ferumoxtran-10 (an ultra-small 20 nm SPION)
provided a combined accuracy of 96%, with 100% sensitivity
and 95% specificity in locating the SLN [43]. Taking
this application one step further, Weissleder et al. haveshown that lymphotrophic SPIONs, injected systemically
as exogenous contrast, can discriminate healthy versus
tumor-burdened nodes by the degree of accumulation of
particles in the nodes [44].
Dual-modality tracers using blue dye and radioisotope
tracer have proven very reliable in many solid organ
tumours, including breast cancer, melanoma, and gastric
cancer [45-47]. This technique facilitates non-invasive
preoperative imaging, coupled with subsequent intraop-
erative assessment, for SLN detection. Blue dye however
is of limited use in esophageal cancer, due to its short
transit time (too short when considering the amount of
time needed to enter the chest cavity), and discoloration
of adjacent tissues, which may obscure the surgical field.
Different dual-modality tracers are needed; perhaps those
using magnetic resonance imaging (MRI) with nanoparti-
cles. MRI has advantages over CT lymphography as it
provides higher spatial and temporal resolution, and
avoids ionizing radiation. We are currently trialing a
dual-modality tracer with both magnetic resonance
imaging capability (using iron oxide) and radioactive
properties (using 99mTc-antimony colloid) in a pig model.
Conclusions
There are two principle ways in which the sentinel lymph
node (SLN) concept could improve staging and thereby
individualized care in patients with esophageal cancer.
First, adoption of the sentinel node biopsy as a staging
investigation (i.e. preoperative lymph node assessment)
could tailor resection of a more superficial esophageal
cancer, and potentially avoid the need for an esophagec-
tomy. Second, identification of the most important lymph
nodes allows the pathologist to “ultra stage” these nodes
with serial sectioning, immunohistochemistry, and/or re-
verse transcriptase polymerase chain reaction. This enables
detection of micrometastatic disease, and identifies a
patient subset that may benefit from adjuvant therapy.
Three limitations to widespread acceptance of the SLN
concept in all solid organ tumors include the lack of a
universally legislated radiocolloid for clinical use, the need
for an invasive procedure to inject the colloid in many
non-superficial cancers, and the inability to have a clear
anatomical pathway preoperatively (due to the “shine
through effect”), to guide intraoperative dissection.
We believe that esophageal cancers should adopt the
SLN concept. This will promote intense research in this
field, and lead to improved tracers capable of not only
non-invasive lymph node staging, but delivery of thera-
peutic agents to disseminated tumor cells within the
nodes. A universally appropriate tracer is also required to
provide consensus and standardization on methodology,
timing of migration, and results of SLN detection. Finally,
improved contrast agents are needed, especially those with
novel dual-modality ‘visibility’.
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